However, in prespecified analyses, there was no evidence of an interaction between sex and treatment effect. Furthermore, no significant differences in CVD outcomes were observed between men and women in a large meta- analysis that included 31 RCTs with about 100000 men and Some have called for a SPRINT-like trial with sufficient power to assess the effects of intensive SBP reduction in women.S10.2.1-2 In meta-analyses, there was no convincing evidence that different antihyperten- sive drug classes exerted sex-related differences in BP low- ering or provided distinct CVD protection.S10.2.1-1 Calcium antagonists offered slightly greater benefits for stroke preven- tion than did ACE inhibitors for women than for men, whereas calcium antagonists reduced all-cause deaths compared with placebo in men but not in women. However, these sex-related differences might have been due to chance because of the large number of statistical comparisons that were performed. The Heart Attack Trial and Hypertension Care Computing Project reported that beta blockers were associated with reduced mor- tality in men but not in women, but this finding was likely due to the low event rates in women.S10.2.1-3 Similarly, in the open-label Second Australian National BP study, a significant reduction in CVD events was demonstrated in men but not in women with ACE inhibitors versus diuretics.S10.2.1-4 Adverse effects of antihypertensive therapy were noted twice as often in women as in men in the TOMHS study.S10.2.1-5 A higher incidence of ACE inhibitor induced cough and of edema with calcium antagonists was observed in women than Women were more likely to experience hypoka- lemia and hyponatremia and less likely to experience gout with Hypertension in pregnancy has special require- ments (see Section 10.2.2). Recommendations for Treatment of Hypertension in Pregnancy References that support recommendations are summarized in Online Data Supplement 53. COR LOE Recommendations I C-LD 1. 